drugset / Trial / NCT03189745

A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).

NCT03189745

Phase 3 Completed 229 enrolled Pfizer
NaParallel-groupOpen-labelPrevention

Summary

This study will evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix) or Mencevax ACWY

Timeline

Start
2017-08-01
Primary completion
2018-04-11
Completion
2018-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Menveo Vaccine